New combo therapy shows promise for Hard-to-Treat breast cancer

NCT ID NCT06612203

Ongoing Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs (Debio 0123 and sacituzumab govitecan) in people with advanced breast cancer that has not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 76 adults with triple-negative or HR+/HER2- breast cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Barts Health NHS Trust

London, United Kingdom
Beatson West of Scotland Cancer Center

Glasgow, United Kingdom
Hospital Arnau de Vilanova de Valencia

Valencia, Spain
Hospital Beata María Ana

Madrid, Spain
Hospital Universitari Dexeus

Barcelona, Spain
Hospital Universitario Clínico San Cecilio de Granada

Granada, Spain
Hospital Universitario Virgen de la Victoria

Málaga, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.